神経芽腫治療薬の世界市場規模調査、タイプ別、投与経路別、流通チャネル別、地域別、予測、2022年～2032年

神経芽腫治療薬の世界市場は、2023年に約7億4,000万米ドルと評価され、予測期間2024-2032年には6.2％以上の健全な成長率で成長すると予測されています。

神経芽細胞腫は、主に5歳以下の幼児に発生するがんで、特に腎臓の上部にある副腎の神経組織に発生します。神経芽細胞と呼ばれる未成熟な神経細胞から発生し、多様な症状と転帰を示すことで知られています。その症状は、腹部のしこり、腸のパターンの変化、骨の不快感、疲労感、皮膚の変化など多岐にわたる。神経芽腫治療薬は、神経芽腫と闘うために調整された薬剤です。シスプラチンやエトポシドのような化学療法剤、ALK遺伝子を標的とするクリゾチニブのような標的療法、ジヌツキシマブのような免疫療法、レチノイン酸のような分化誘導剤、i-131 MIBGのような放射性医薬品が含まれます。治療計画は、がんの病期や患者の健康状態などの要因に基づいて個別化され、効果を最適化するために専門家チームによって設計された治療法の組み合わせが含まれます。個別化医療や標的治療へのシフトが高まっていることは、世界の神経芽腫治療薬市場にとって重要な動向です。医薬品開発者は、神経芽腫に関連する遺伝子異常や生物学的プロセスを特異的に標的とする医薬品の開発に一層注力しています。この方法は、より集中的かつ効率的な治療を可能にすることで、副作用を軽減し、患者の転帰を向上させる。

さらに、神経芽腫治療薬市場に影響を与える主な促進要因には、医療技術の進歩が含まれ、神経芽腫患者の診断と治療選択肢の改善につながります。さらに、神経芽腫に関する認知度の向上と早期発見への取り組みが神経芽腫治療薬の需要に寄与しています。さらに、標的療法や免疫療法の開発に焦点を当てた研究開発が進められていることも、市場の成長をさらに後押ししています。製薬会社は、この疾患に対するより効果的な治療法に対するアンメットニーズのために、新しい神経芽腫治療薬の研究開発（R&D）に多額の投資を行っています。このような研究開発活動の活発化の結果、患者の予後を改善する可能性のある神経芽腫の新薬がいくつか開発中です。さらに、製薬会社、学術機関、ヘルスケア組織間のコラボレーションは、イノベーションを促進し、新規の神経芽腫治療薬を市場に導入することで、推定期間中、世界の神経芽腫治療薬市場にさまざまな成長見通しをもたらしています。しかし、神経芽腫治療薬に関連する副作用や医薬品承認に対する厳しい規制要件が、2022年から2032年にかけての世界の神経芽腫治療薬市場の成長を阻害すると予想されています。

神経芽腫治療薬の世界市場調査において考慮した主要地域には、アジア太平洋地域、北米、欧州、ラテンアメリカ、その他世界のその他の地域が含まれます。2023年には、北米が神経芽腫治療薬市場で支配的な地位を占めました。これは、神経芽腫治療薬の利用可能性の上昇、政府の支援イニシアティブ、強固な規制の裏付け、確立されたヘルスケアシステムなどのいくつかの要因によるものです。さらに、この地域は、製品承認やパートナーシップのような戦略的イニシアチブに積極的に取り組んでいる主要な業界プレイヤーの存在感が大きく、北米の市場拡大に大きく貢献しています。一方、アジア太平洋地域は予測期間中に急成長を遂げようとしています。

目次

第1章 神経芽腫治療薬の世界市場定義と調査前提条件

• 調査目的
• 市場の定義
• 調査前提条件
  • 包含と除外
  • 制限事項
  • 供給サイドの分析
    • 入手可能性
    • インフラ
    • 規制環境
    • 市場競争
    • 経済性（消費者の視点）
  • 需要サイド分析
    • 規制の枠組み
    • 技術の進歩
    • 環境への配慮
    • 消費者の意識と受容
• 調査手法
• 調査対象年
• 通貨換算レート

第2章 エグゼクティブサマリー

• 神経芽腫治療薬の世界市場規模・予測（2022年～2032年）
• 地域別概要
• セグメント別概要
  • タイプ別
  • 投与経路別
  • 流通チャネル別
• 主要動向
• 景気後退の影響
• アナリストの結論・提言

第3章 神経芽腫治療薬の世界市場力学

• 市場促進要因
• 市場の課題
• 市場機会

第4章 神経芽腫治療薬の世界市場産業分析

• ポーターのファイブフォースモデル
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
  • ポーターの5フォースモデルへの未来的アプローチ
  • ポーター5フォースの影響分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 環境
  • 法律
• 主な投資機会
• 主要成功戦略
• 破壊的動向
• 業界専門家の視点
• アナリストの結論・提言

第5章 神経芽腫治療薬の世界市場規模・予測：タイプ別、2022年～2032年

• 化学療法
• 免疫療法
• その他

第6章 神経芽腫治療薬の世界市場規模・予測：投与経路別、2022年～2032年

• 経口剤
• 注射剤

第7章 神経芽腫治療薬の世界市場規模・予測：流通チャネル別、2022年～2032年

• オンライン
• オフライン

第8章 神経芽腫治療薬の世界市場規模・予測：地域別、2022年～2032年

• 北米の神経芽腫治療薬市場
  • 米国
    • タイプ別内訳：規模および予測、2022-2032年
    • 投与経路別内訳：規模および予測、2022-2032年
    • 流通チャネル別内訳：規模および予測、2022-2032年
  • カナダの神経芽腫治療薬市場
• 欧州の神経芽腫治療薬市場
  • 英国の神経芽腫治療薬市場
  • ドイツの神経芽腫治療薬市場
  • フランスの神経芽腫治療薬市場
  • スペインの神経芽腫治療薬市場
  • イタリアの神経芽腫治療薬市場
  • その他欧州の神経芽腫治療薬市場
• アジア太平洋神経芽腫治療薬市場
  • 中国の神経芽腫治療薬市場
  • インドの神経芽腫治療薬市場
  • 日本の神経芽腫治療薬市場
  • オーストラリアの神経芽腫治療薬市場
  • 韓国の神経芽腫治療薬市場
  • その他アジア太平洋地域の神経芽腫治療薬市場
• ラテンアメリカの神経芽腫治療薬市場
  • ブラジルの神経芽腫治療薬市場
  • メキシコの神経芽腫治療薬市場
  • その他ラテンアメリカの神経芽腫治療薬市場
• 中東・アフリカの神経芽腫治療薬市場
  • サウジアラビアの神経芽腫治療薬市場
  • 南アフリカの神経芽腫治療薬市場
  • その他中東とアフリカの神経芽腫治療薬市場

第9章 競合情報

• 主要企業のSWOT分析
• 主要市場戦略
• 企業プロファイル
  • Recordati Group
    • 主要情報
    • 概要
    • 財務（データの入手可能性によります）
    • 製品概要
    • 市場戦略
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Y-mabs Therapeutics, Inc.
  • MacroGenics Inc.
  • AstraZeneca plc
  • United Therapeutics Corporation
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Cellectar Biosciences, Inc.

第10章 調査プロセス

• 調査プロセス
  • データマイニング
  • 分析
  • 市場推定
  • 検証
  • 出版
• 調査属性

LIST OF TABLES

• TABLE 1. Global Neuroblastoma Drugs Market, report scope
• TABLE 2. Global Neuroblastoma Drugs Market estimates & forecasts by Region 2022-2032 (USD Million)
• TABLE 3. Global Neuroblastoma Drugs Market estimates & forecasts by Type 2022-2032 (USD Million)
• TABLE 4. Global Neuroblastoma Drugs Market estimates & forecasts by Route of Administration 2022-2032 (USD Million)
• TABLE 5. Global Neuroblastoma Drugs Market estimates & forecasts by Distribution Channel 2022-2032 (USD Million)
• TABLE 6. Global Neuroblastoma Drugs Market by segment, estimates & forecasts, 2022-2032 (USD Million)
• TABLE 7. Global Neuroblastoma Drugs Market by region, estimates & forecasts, 2022-2032 (USD Million)
• TABLE 8. Global Neuroblastoma Drugs Market by segment, estimates & forecasts, 2022-2032 (USD Million)
• TABLE 9. Global Neuroblastoma Drugs Market by region, estimates & forecasts, 2022-2032 (USD Million)
• TABLE 10. Global Neuroblastoma Drugs Market by segment, estimates & forecasts, 2022-2032 (USD Million)
• TABLE 11. Global Neuroblastoma Drugs Market by region, estimates & forecasts, 2022-2032 (USD Million)
• TABLE 12. Global Neuroblastoma Drugs Market by segment, estimates & forecasts, 2022-2032 (USD Million)
• TABLE 13. Global Neuroblastoma Drugs Market by region, estimates & forecasts, 2022-2032 (USD Million)
• TABLE 14. Global Neuroblastoma Drugs Market by segment, estimates & forecasts, 2022-2032 (USD Million)
• TABLE 15. Global Neuroblastoma Drugs Market by region, estimates & forecasts, 2022-2032 (USD Million)
• TABLE 16. U.S. Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
• TABLE 17. U.S. Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 18. U.S. Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 19. Canada Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
• TABLE 20. Canada Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 21. Canada Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 22. UK Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
• TABLE 23. UK Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 24. UK Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 25. Germany Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
• TABLE 26. Germany Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 27. Germany Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 28. France Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
• TABLE 29. France Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 30. France Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 31. Italy Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
• TABLE 32. Italy Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 33. Italy Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 34. Spain Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
• TABLE 35. Spain Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 36. Spain Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 37. RoE Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
• TABLE 38. RoE Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 39. RoE Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 40. China Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
• TABLE 41. China Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 42. China Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 43. India Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
• TABLE 44. India Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 45. India Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 46. Japan Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
• TABLE 47. Japan Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 48. Japan Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 49. Australia Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
• TABLE 50. Australia Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 51. Australia Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 52. South Korea Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
• TABLE 53. South Korea Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 54. South Korea Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 55.
• TABLE 56. RoAPAC Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
• TABLE 57. RoAPAC Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 58. RoAPAC Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 59. Brazil Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
• TABLE 60. Brazil Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 61. Brazil Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 62. Mexico Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
• TABLE 63. Mexico Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 64. Mexico Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 65. RoLA Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
• TABLE 66. RoLA Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 67. RoLA Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 68. Saudi Arabia Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
• TABLE 69. Saudi Arabia Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
• TABLE 70. Saudi Arabia Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
• TABLE 71. South Africa Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 72.
• TABLE 73. South Africa Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 74. South Africa Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 75. RoMEA Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 76. RoMEA Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 77. RoMEA Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
• TABLE 78. List of secondary sources, used in the study of Global Neuroblastoma Drugs Market.
• TABLE 79. List of primary sources, used in the study of Global Neuroblastoma Drugs Market.
• TABLE 80. Years considered for the study.
• TABLE 81. Exchange rates considered.

LIST OF FIGURES

• FIG 1. Global Neuroblastoma Drugs Market, research methodology
• FIG 2. Global Neuroblastoma Drugs Market, market estimation techniques
• FIG 3. Global market size estimates & forecast methods.
• FIG 4. Global Neuroblastoma Drugs Market, key trends 2023
• FIG 5. Global Neuroblastoma Drugs Market, growth prospects 2022-2032
• FIG 6. Global Neuroblastoma Drugs Market, porters 5 force model
• FIG 7. Global Neuroblastoma Drugs Market, pestel analysis
• FIG 8. Global Neuroblastoma Drugs Market, value chain analysis
• FIG 9. Global Neuroblastoma Drugs Market by segment, 2022 & 2032 (USD Million)
• FIG 10. Global Neuroblastoma Drugs Market by segment, 2022 & 2032 (USD Million)
• FIG 11. Global Neuroblastoma Drugs Market by segment, 2022 & 2032 (USD Million)
• FIG 12. Global Neuroblastoma Drugs Market by segment, 2022 & 2032 (USD Million)
• FIG 13. Global Neuroblastoma Drugs Market by segment, 2022 & 2032 (USD Million)
• FIG 14. Global Neuroblastoma Drugs Market, regional snapshot 2022 & 2032
• FIG 15. North America Neuroblastoma Drugs Market 2022 & 2032 (USD Million)
• FIG 16. Europe Neuroblastoma Drugs Market 2022 & 2032 (USD Million)
• FIG 17. Asia pacific Neuroblastoma Drugs Market 2022 & 2032 (USD Million)
• FIG 18. Latin America Neuroblastoma Drugs Market 2022 & 2032 (USD Million)
• FIG 19. Middle East & Africa Neuroblastoma Drugs Market 2022 & 2032 (USD Million)
• FIG 20. Global Neuroblastoma Drugs Market, company market share analysis (2023)

Global Neuroblastoma Drugs Market is valued approximately USD 740 million in 2023 and is anticipated to grow with a healthy growth rate of more than 6.2% over the forecast period 2024-2032. Neuroblastoma is a cancer primarily occurring in young children below five years old, originating in nerve tissue specifically in the adrenal glands atop the kidneys. It emerges from immature nerve cells, called neuroblasts, known for its diverse symptoms and outcomes. These range from abdominal lumps, altered bowel patterns, bone discomfort, fatigue, to skin alterations, showcasing its varied presentation. Neuroblastoma drugs are medications tailored to combat neuroblastoma. It encompasses chemotherapy agents like cisplatin and etoposide, targeted therapies such as crizotinib targeting the ALK gene, immunotherapies like dinutuximab, differentiation agents like retinoic acid, and radiopharmaceuticals like I-131 MIBG. Treatment plans are individualized based on factors like the cancer stage and patient's health involving a combination of therapies designed by a team of specialists to optimize effectiveness. The rising shift towards personalized medicine and targeted therapies is a key trend for the Global Neuroblastoma Drugs Market. Drug developers are concentrating more on creating medications that specifically target genetic abnormalities or biological processes associated with neuroblastoma. This method reduces adverse effects and enhances patient outcomes by enabling more focused and efficient therapy.

In addition, the key driving factors influencing the Neuroblastoma Drugs market include advancements in medical technology, leading to improved diagnosis and treatment options for neuroblastoma patients. Additionally, increased awareness about neuroblastoma and early detection initiatives contribute to the demand for neuroblastoma drugs. Moreover, ongoing research and development efforts focused on developing targeted therapies and immunotherapies further propel market growth. Pharmaceutical companies are heavily investing in research and development (R&D) of new neuroblastoma drugs to the unmet need for more effective treatments for this disease. As a result of this increased R&D activity, there are several new neuroblastoma drugs in the pipeline that have the potential to improve outcomes for patients. Furthermore, collaborations between pharmaceutical companies, academic institutions, and healthcare organizations foster innovation and the introduction of novel neuroblastoma drugs into the market, which are further presenting various growth prospects to the Global Neuroblastoma Drugs Market during the estimated period. However, adverse side effects associated with neuroblastoma drugs and stringent regulatory requirement for drug approvals are expected to stifle Global Neuroblastoma Drugs Market growth between 2022 and 2032.

The key regions considered for the global Neuroblastoma Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America held the dominant position in the neuroblastoma drugs market due to several factors such as rising availability of neuroblastoma drugs, supportive governmental initiatives, robust regulatory backing, and a well-established healthcare system. Moreover, the region benefits from the significant presence of key industry players that are actively engaged in strategic initiatives like product approvals and partnerships, contributing significantly to market expansion in North America. On the other hand, Asia Pacific is poised for rapid growth over the forecast period.

Major market player included in this report are:

• Recordati Group
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Y-mabs Therapeutics, Inc.
• MacroGenics Inc.
• AstraZeneca plc
• United Therapeutics Corporation
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Cellectar Biosciences, Inc.

The detailed segments and sub-segment of the market are explained below:

By Type

• Chemotherapy
• Immunotherapy
• Others

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Online
• Offline

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Neuroblastoma Drugs Market Definition and Research Assumptions

• 1.1. Research Objective
• 1.2. Market Definition
• 1.3. Research Assumptions
  • 1.3.1. Inclusion & Exclusion
  • 1.3.2. Limitations
  • 1.3.3. Supply Side Analysis
    • 1.3.3.1. Availability
    • 1.3.3.2. Infrastructure
    • 1.3.3.3. Regulatory Environment
    • 1.3.3.4. Market Competition
    • 1.3.3.5. Economic Viability (Consumer's Perspective)
  • 1.3.4. Demand Side Analysis
    • 1.3.4.1. Regulatory frameworks
    • 1.3.4.2. Technological Advancements
    • 1.3.4.3. Environmental Considerations
    • 1.3.4.4. Consumer Awareness & Acceptance
• 1.4. Estimation Methodology
• 1.5. Years Considered for the Study
• 1.6. Currency Conversion Rates

Chapter 2. Executive Summary

• 2.1. Global Neuroblastoma Drugs Market Size & Forecast (2022- 2032)
• 2.2. Regional Summary
• 2.3. Segmental Summary
  • 2.3.1. By Type
  • 2.3.2. By Route of Administration
  • 2.3.3. By Distribution Channel
• 2.4. Key Trends
• 2.5. Recession Impact
• 2.6. Analyst Recommendation & Conclusion

Chapter 3. Global Neuroblastoma Drugs Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Challenges
• 3.3. Market Opportunities

Chapter 4. Global Neuroblastoma Drugs Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Neuroblastoma Drugs Market Size & Forecasts by Type 2022-2032

• 5.1. Chemotherapy
• 5.2. Immunotherapy
• 5.3. Others

Chapter 6. Global Neuroblastoma Drugs Market Size & Forecasts by Route of Administration 2022-2032

• 6.1. Oral
• 6.2. Injectable

Chapter 7. Global Neuroblastoma Drugs Market Size & Forecasts by Distribution Channel 2022-2032

• 7.1. Online
• 7.2. Offline

Chapter 8. Global Neuroblastoma Drugs Market Size & Forecasts by Region 2022-2032

• 8.1. North America Neuroblastoma Drugs Market
  • 8.1.1. U.S. Neuroblastoma Drugs Market
    • 8.1.1.1. Type breakdown size & forecasts, 2022-2032
    • 8.1.1.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 8.1.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
  • 8.1.2. Canada Neuroblastoma Drugs Market
• 8.2. Europe Neuroblastoma Drugs Market
  • 8.2.1. U.K. Neuroblastoma Drugs Market
  • 8.2.2. Germany Neuroblastoma Drugs Market
  • 8.2.3. France Neuroblastoma Drugs Market
  • 8.2.4. Spain Neuroblastoma Drugs Market
  • 8.2.5. Italy Neuroblastoma Drugs Market
  • 8.2.6. Rest of Europe Neuroblastoma Drugs Market
• 8.3. Asia-Pacific Neuroblastoma Drugs Market
  • 8.3.1. China Neuroblastoma Drugs Market
  • 8.3.2. India Neuroblastoma Drugs Market
  • 8.3.3. Japan Neuroblastoma Drugs Market
  • 8.3.4. Australia Neuroblastoma Drugs Market
  • 8.3.5. South Korea Neuroblastoma Drugs Market
  • 8.3.6. Rest of Asia Pacific Neuroblastoma Drugs Market
• 8.4. Latin America Neuroblastoma Drugs Market
  • 8.4.1. Brazil Neuroblastoma Drugs Market
  • 8.4.2. Mexico Neuroblastoma Drugs Market
  • 8.4.3. Rest of Latin America Neuroblastoma Drugs Market
• 8.5. Middle East & Africa Neuroblastoma Drugs Market
  • 8.5.1. Saudi Arabia Neuroblastoma Drugs Market
  • 8.5.2. South Africa Neuroblastoma Drugs Market
  • 8.5.3. Rest of Middle East & Africa Neuroblastoma Drugs Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Recordati Group
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Market Strategies
  • 9.3.2. Eli Lilly and Company
  • 9.3.3. Bristol-Myers Squibb Company
  • 9.3.4. Y-mabs Therapeutics, Inc.
  • 9.3.5. MacroGenics Inc.
  • 9.3.6. AstraZeneca plc
  • 9.3.7. United Therapeutics Corporation
  • 9.3.8. Pfizer Inc.
  • 9.3.9. Teva Pharmaceutical Industries Ltd.
  • 9.3.10. Cellectar Biosciences, Inc.

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes